x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

DarshanTalks Podcast

Darshan Kulkarni

Welcome to DarshanTalks!We demystify fraud for legal, regulatory, and compliance essentials in the life sciences and pharmacy industries. Through engaging 15-30-minute interviews with influential change makers, short educational regulatory defbriefs, and 60 second audio takeaways, we unveil the strategies behind bringing drugs and devices to market—and keeping them there!Powered By The Kulkarni Law Firm - Helping regulators see your business the way you do.We focus on life science issues involving

science life sciences

All Episodes

1:39

The Messy Reality of AI Prescriptions

DarshanTalks Podcast ·

2026/03/08

Send a text State governments are racing to innovate by allowing AI to renew and improve prescriptions—but are they walking into a federal trap? In this episode of KLF Deep Dive, Darshan Kulkarni breaks down the "Utah Sandbox" model and the three massive warning signs flashing for the life sciences industry. From misdiagnosis risks to the nightmare of liability ownership, we explore why "innovation" doesn't grant immunity from federal law or malpractice lawsuits. If you are a healthcare execu...

en-us

1:37

Why Your Consultant’s Report Is a Legal Liability

DarshanTalks Podcast ·

2026/03/07

Send a text In the high-stakes world of Life Science M&A, hiring expert consultants for GXP, IT, and data privacy is standard operating procedure. But there is a hidden structural flaw in most due diligence programs: Scope Creep. When a consultant identifies "high risk" in a data transfer mechanism, they aren't just giving a business metric—they are venturing into legal opinion. Without the protection of attorney-client privilege, these "compliance scorecards" and "heat maps" are discover...

en-us

5:32

Stop Reporting Results? The NIH’s "Get Out of Jail...

DarshanTalks Podcast ·

2026/03/06

Send a text The NIH just dropped a regulatory bombshell: Notice NOT-OD-26-032. Effectively immediately, Basic Experimental Studies in Humans (BESH) are no longer classified as "Clinical Trials" for reporting purposes. Is this a victory for common sense, or an administrative "fudge" to hide years of academic non-compliance? In this episode, Darshan Kulkarni breaks down why this "Great Reset" changes the mathematics of due diligence, tech transfer, and company valuations. If you are licen...

en-us

2:24

Final LGBTQ Individuals in clinical research

DarshanTalks Podcast ·

2026/03/05

Send a text Support the show www.kulkarnilawfirm.com

en-us

3:29

When the FDA Plays Politics

DarshanTalks Podcast ·

2026/03/04

Send a text In this episode of KLF Deep Dive, we examine a chilling shift in regulatory enforcement: the weaponization of "Intended Use." If the science hasn't changed and the law hasn't changed, why is the FDA pivoting from "advice-giving" to "subpoena-swinging"? Host Darshan Kulkarni breaks down the legal whiplash between the Ivermectin era and the current crackdown on gender-affirming care. We explore why the "Practice of Medicine" shield is disappearing and what this "Rule of the Mood" me...

en-us

0:33

Your Site’s Background Check is Illegally Incomplete...

DarshanTalks Podcast ·

2026/03/03

Send a text In this episode, Darshan Kulkarni dives into the terrifying reality of compliance failures at clinical trial sites. While most directors worry about standard fines, the true danger lies in the "off-the-book" penalties and the looming threat of criminal prosecution for employing excluded physicians. If you aren't auditing your lists correctly, you aren't just risking a citation—you're risking your entire career. Support the show www.kulkarnilawfirm.com

en-us

5:34

Is Your Off-Label Use Now a Federal Crime?

DarshanTalks Podcast ·

2026/03/02

Send a text For decades, a "clean mental line" existed: Doctors prescribe, and companies don't promote off-label. That line just got a lot messier. In this episode, Darshan Kulkarni breaks down the Hsaio Declaration—a seismic shift in DOJ enforcement that aims to turn independent medical judgment into evidence of a federal crime. We dive into the University of Pittsburgh Medical Center (UPMC) subpoena battle, the fallout of Executive Order 14187, and why "Scientific Exchange" may no longer be...

en-us

14:25

Futurist Bruce McCabe: How Narrow AI is Solving...

DarshanTalks Podcast ·

2026/02/23

In this episode, we sit down with world-renowned futurist Bruce McCabe to cut through the hype of large language models like ChatGPT and explore the "stunningly optimistic" reality of Specialist (Narrow) AI. Bruce shares insights from his global travels to research labs, explaining why the future of medicine isn’t one "God-like" AI, but rather a "hive mind" of tens of thousands of highly trained, testable, and trustworthy specialist systems. From early tumor detection in radiology to the revo...

en-us

15:29

The Battle Over Weight Loss and Compounded Drugs

DarshanTalks Podcast ·

2026/02/16

In this episode of DarshanTalks, host and attorney-pharmacist Darshan Kulkarni deconstructs the legal "scorched-earth" offensive currently reshaping the weight loss drug industry. Following the February 2026 announcement that the GLP-1 shortage is officially resolved, the "Golden Age" for compounders has vanished overnight, leaving companies like Hims & Hers in the crosshairs of both the FDA and Novo Nordisk. Darshan takes us from the tragic "ghost" of the 2012 NECC fungal meningitis ou...

en-us

18:09

Why Cosmetic Ingredient Names Matter and What MOCRA...

DarshanTalks Podcast ·

2026/01/29

In this episode, I sit down with FDA compliance attorney Heather Butos to unpack two topics most cosmetic pros ignore until it’s too late: INCI (ingredient) names and MOCRA (the new cosmetic law). We talk about how ingredient naming is not just labeling, it’s a strategic business decision that can make or break product marketing. Heather breaks down how the Personal Care Products Council influences naming conventions, why companies struggle to sell ingredients when they can’t describe them we...

en-us

25:54

Compliance Isn’t a Deal Killer… Until It Is -...

DarshanTalks Podcast ·

2026/01/22

Life sciences M&A is picking up again, but today’s deals look nothing like they did two years ago. In this episode, Darshan Kulkarni sits down with Stephanie Trunk, Partner at ArentFox Schiff, to unpack what’s really driving renewed deal activity and what buyers are still missing in diligence. From U.S. manufacturing incentives and drug pricing exposure to China risk, DOJ enforcement, compliance culture, and AI, this conversation goes beyond headlines and into deal reality. If you are buy...

en-us

2:24

Cosmetic ingredients the FDA doesn’t want you to use

DarshanTalks Podcast ·

2026/01/17

A brief discussion on the various cosmetic ingredients used by cosmetic manufacturers and the concerns FDA has recently found as a result of their own study into the process Support the show www.kulkarnilawfirm.com

en-us

8:04

Why Federal Agencies Are Targeting Executives

DarshanTalks Podcast ·

2026/01/15

Federal enforcement is changing. Regulators aren’t just going after companies anymore. They’re naming CEOs, CMOs, heads of clinical, quality, and operations in consent decrees and injunctions. Once your name is on that document, it follows you for years and shapes your career. In this episode we unpack: Why enforcement has shifted toward individual accountabilityHow repeated compliance failures trigger personal liabilityData integrity and why it matters more than everWhy clinical research and...

en-us

1:14

Why the New Food Pyramid Matters to You

DarshanTalks Podcast ·

2026/01/10

Everyone’s talking about the new food pyramid like it’s diet advice. I’m here to tell you it’s regulatory policy in disguise. In this episode I break down why this change matters beyond grocery aisles: school meal rules, food labeling, federal purchasing, and how the government quietly reshapes what counts as “healthy.” If you think this is just about fats and grains, think again. This affects prices, marketing claims, and what ends up on kids’ plates. I’m a food and drug lawyer focused...

en-us

29:59

Ex FDA Commissioner Robert Califf on FDA Authority,...

DarshanTalks Podcast ·

2026/01/08

Episode Description In this episode, Darshan Kulkarni sits down with former FDA Commissioner Robert Califf for a wide-ranging conversation on FDA authority, politics, guidance, and public trust. From the loss of Chevron deference to the role of FDA as a referee, Dr. Califf explains how regulation really works and why wealth inequality has become the most serious health issue in the United States. Episode Summary What does it really take to run the FDA, and how political should the agency be? ...

en-us

8:58

Buying a Med Spa? GLP-1 Compliance Can Kill the Deal

DarshanTalks Podcast ·

2026/01/08

GLP-1 weight loss programs are everywhere right now, especially in the med spa space. For M&A lawyers and deal teams, that popularity comes with serious regulatory risk. In this episode, Darshan breaks down why GLP-1 compliance has quietly become a dealbreaker in healthcare acquisitions. What used to be framed as an FDA issue is now actively being enforced by state attorneys general using consumer protection and deceptive trade practice laws. You’ll hear how the end of the FDA shortage ch...

en-us

1:10

New crown jewel valuing patient data

DarshanTalks Podcast ·

2026/01/02

For decades, biotech M&A followed a familiar script. Patents drove value. Molecules closed deals. That script is breaking. In today’s precision medicine transactions, the real asset is data. Longitudinal patient records, real-world evidence, and genomic datasets are now central to valuation. But unlike traditional IP, data comes with strings attached. Privacy laws, patient consent, and transfer restrictions can quietly determine whether that data is an asset or a liability. In this episod...

en-us

0:46

Your Staff is trained, but can you prove it?

DarshanTalks Podcast ·

2025/12/26

Staffing and training are not just operational issues. They are inspection risks. In this episode, we break down what sponsors and regulators actually expect when it comes to site staff training. Competent staff is not enough if training is not documented. We walk through common failure points seen during FDA inspections, including missing GCP documentation, unclear staff roles, and poor escalation processes. We also discuss how structured SOPs, training logs, and clear contracts with coordin...

en-us

0:59

What Happens When a Sponsor Walks Away Early?

DarshanTalks Podcast ·

2025/12/23

Early termination by a sponsor can leave a clinical research site holding the bill for prep work, fees, and staffing. In this episode, Darshan explains the contract language every site should insist on to stay protected. He covers guaranteed payment for all work performed up to the termination date, reimbursement for non-cancelable expenses like IRB fees and advertising, and why a wind-down clause is essential for chart reviews, final visits, and data queries. He also explores when mini...

en-us

6:53

Cosmetic Claims the FDA Hates

DarshanTalks Podcast ·

2025/12/22

Your skincare product may look like a cosmetic, but one wrong claim can legally turn it into an unapproved drug. In this episode of KLF Deep Dive, we break down the exact words, phrases, and influencer mistakes that push cosmetic brands straight into FDA drug territory. Anti-inflammatory claims. Acne treatment language. Collagen rebuilding promises. Detox buzzwords. These are not harmless marketing fluff. They are regulatory landmines. We explain how the FDA actually classifies products, why ...

en-us

310 results

Similar Podcasts

Classic Radio Science Fiction

solgoodmedia.com

Mission to Mars

Inception Point Ai

The 365 Days of Astronomy

365DaysOfAstronomy.org

Creek Devil

william Jevning

UFO Chronicles Podcast

Nik Hunter